A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
← catalyst calendarSponsored by Nuvectis Pharma, Inc. (industry) · NVCT — their whole pipeline →. With Gynecologic Oncology Group Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT).
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
45actual
Sites
22
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Why the sponsor stopped it
Study terminated due to various reasons impacting the feasibility of future clinical development
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-31 | actual | When the study began enrolling |
| Primary completion | 2025-01-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-01-01 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Ovarian Cancer
- Ovarian Clear Cell Carcinoma
- Ovarian Clear Cell Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Endometrioid Tumor
- ARID1A Gene Mutation
Intervention
- Drug: NXP800
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities
measured Day 28
Part B: Estimates of disease response by RECIST v 1.1
measured Baseline to 30 days post last dose of NXP800
Part B: Number of patients with treatment related adverse events, and/or clinical laboratory abnormalities.
measured Baseline to 30 days post last dose of NXP800
Related
NVCT · their whole pipeline · Solid Tumors readouts
NVCT's other studiesmost recently updated first
- Study of NXP900 With Lorlatinib in ALK+ Lung Cancer Phase 1 · Recruiting
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers Phase 1 · Recruiting
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Phase 1 · Recruiting
Permalink · NVCT's whole pipeline · Catalyst calendar · Every registered study · What changed